Product Information
PHOSPHA 250 NEUTRAL TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.3976 per EA under NDC 64980010401. Its NADAC has been published 666 times since Nov 28, 2013.
PHOSPHA 250 NEUTRAL TABLET
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateStrength
155; 852; 130 mg/1; mg/1; mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980010401
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
POTASSIUM PHOSPHATE, MONOBASIC; SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEApproval Type
Unapproved
On Market Since
6/28/2012
Price Statistics
The NADAC for PHOSPHA 250 NEUTRAL TABLET has been published 666 times since Nov 28, 2013, and over the history we have for it it has risen 182.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3976 per EA |
|---|---|
| All-time high | $0.3976 (Sep 30, 2026) |
| All-time low | $0.1406 (Nov 28, 2013) |
| 52-week high | $0.3976 |
| 52-week low | $0.1897 |
| Median price | $0.2469 |
| Average price | $0.2566 |
| Largest weekly change | +59.1% (Jan 22, 2014) |
| Weeks tracked | 666 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHOSPHA 250 NEUTRAL TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PHOSPHA 250 NEUTRAL TABLET, manufactured by Rising Pharma Holdings Inc., is $0.3976 per EA (NDC 64980010401), effective Sep 30, 2026.
How has the price of PHOSPHA 250 NEUTRAL TABLET changed over time?
Over the history we have for it, the NADAC for PHOSPHA 250 NEUTRAL TABLET has risen 182.7%. It has been tracked across 666 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PHOSPHA 250 NEUTRAL TABLET?
Since Nov 28, 2013, the NADAC for PHOSPHA 250 NEUTRAL TABLET has ranged from a low of $0.1406 (Nov 28, 2013) to a high of $0.3976 (Sep 30, 2026), with a median of $0.2469 per EA.
Are there cheaper alternatives to PHOSPHA 250 NEUTRAL TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PHOSPHA 250 NEUTRAL TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PHOSPHA 250 NEUTRAL TABLET?
PHOSPHA 250 NEUTRAL TABLET (NDC 64980010401) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.